Biostar Appoints Deyin Chen as CFO
Biostar Pharmaceuticals, the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, has appointed Deyin ‘Bill’ Chen as chief financial officer (CFO). Chen replaces Elaine Zhao, who resigned.
Chen brings more than 13 years of multinational and Big 4 accounting experiences to Biostar. His expertise includes financial management, financing transactions, corporate governance and investor relations. Most recently, Chen was an independent advisor engaged in local renminbi (RMB) private equity (PE) fundraising and providing merger and acquisition (M&A) and PE advisory and due diligence services. Prior to that, he was a partner of Trenwith Securities, where he was engaged in and executed cross-border equity financing for various Chinese companies. He was also a senior business advisor of Ernst & Young and a senior financial advisor of IBM Global Services. From 1997 to 2000, Chen was the CFO for China Operations of Ashland.
Chen graduated with a Bachelor’s degree in Nuclear Physics from Fudan University, and MSc degree in Nuclear Engineering and Accountancy from University of Cincinnati. He also holds a MBA degree from York University.